COMMD3 and breast carcinoma: In other words, for patients with luminal-A-like breast cancer who were still alive seven years after diagnosis, survival probability was lower for tumours lacking COMMD3 (e.g., 72.5% of patients alive at 10 years post-diagnosis, verus 83% for COMMD3 + cases (Fig-2H)).